Rybelsus N
Rybelsus N is an originator product from Novo Nordisk Pharma AG and is listed on the FOPH Specialities List. Swiss mandatory health insurance therefore reimburses it within the authorised indication. The public price ranges from CHF 113.50 to CHF 307.65 depending on the pack; the patient co-payment is 10 per cent plus the deductible.
Core data
- Authorisation holder
- Novo Nordisk Pharma AG
- ATC code
- A10BJ06
- IT group
- 07.06.20 Orale blutzuckersenkende Mittel
- Active substances
- Semaglutidum
- Preparation type
- Originator product
- On the SL since
- 01/04/2026
- Last price change
- 01/04/2026
- Co-payment
- 10%
Prices per pack
The ex-factory price is the authorisation holder's price; the public price adds the distribution share and VAT. Both are FOPH maximum prices: nothing above them may be charged.
| Dosage form | Pack size | Ex-factory price | Public price | Valid from | Cat. | GTIN |
|---|---|---|---|---|---|---|
| Tabl 1.5 mg | Blist 30 Stk | CHF 89.26 | CHF 113.50 | 01/04/2026 | B | 7680698650010 |
| Tabl 4 mg | Blist 30 Stk | CHF 89.26 | CHF 113.50 | 01/04/2026 | B | 7680698650027 |
| Tabl 4 mg | Blist 90 Stk | CHF 267.78 | CHF 307.65 | 01/04/2026 | B | 7680698650034 |
| Tabl 9 mg | Blist 30 Stk | CHF 89.26 | CHF 113.50 | 01/04/2026 | B | 7680698650041 |
| Tabl 9 mg | Blist 90 Stk | CHF 267.78 | CHF 307.65 | 01/04/2026 | B | 7680698650058 |
Limitation
This preparation is reimbursed only under the conditions below. The text is the binding FOPH wording; outside those conditions basic insurance does not pay.
The FOPH publishes limitation texts in German, French and Italian only. The German wording is reproduced verbatim below.
- In Monotherapie bei Patienten mit nachgewiesener Kontraindikation oder nachgewiesener Unverträglichkeit für Metformin.
Zur Behandlung von Patienten mit einem Typ 2 Diabetes mellitus in Kombination mit folgenden Therapieoptionen, wenn durch diese Antidiabetika keine ausreichende Blutzuckerkontrolle erreicht wird:
- Als Zweifachkombination mit Metformin oder einem Sulfonylharnstoff
- Als Dreifachkombination mit einer Kombination aus Metformin und einem Sulfonylharnstoff
- In Kombination mit Basalinsulin mit oder ohne Metformin
- In Kombination mit einem SGLT-2-Inhibitor mit oder ohne Metformin
Mindestens BMI 28. Zusätzliche Medikamente zur Gewichtsreduktion werden nicht vom Krankenversicherer vergütet.
More preparations in this group
FAQ
Is Rybelsus N covered by Swiss health insurance?
Yes, but only under conditions. Rybelsus N is on the Specialities List with a limitation: basic insurance reimburses it only when the conditions in the limitation text are met, in some cases only after the insurer has granted cost approval.
What does Rybelsus N cost in Switzerland?
The public price is the maximum price set by the FOPH and for Rybelsus N ranges from CHF 113.50 to CHF 307.65 per pack. The ex-factory price ranges from CHF 89.26 to CHF 267.78. Pharmacies may not charge more, but may charge less.
Market access
Do you need your product on the Specialities List?
Questions about SL listing, prices or limitations? Contact Swiss Reimbursement.
- Independent directory
- Official FOPH data
- Website in eight languages